import type { TerritoryMultiplier } from '@/types';

export const TERRITORY_MULTIPLIERS: TerritoryMultiplier[] = [
  {
    territory: 'United States',
    code: 'US',
    multiplier: 1.00,
    population_m: 336,
    gdp_per_capita_usd: 76000,
    healthcare_spend_pct: 17.8,
    notes: 'Reference market. Premium pricing environment. Largest single pharmaceutical market globally.',
  },
  {
    territory: 'EU5 (Combined)',
    code: 'EU5',
    multiplier: 1.45,
    population_m: 330,
    gdp_per_capita_usd: 43000,
    healthcare_spend_pct: 10.8,
    notes: 'Combined EU5 market. Lower pricing than US but larger combined patient base.',
  },
  {
    territory: 'Germany',
    code: 'Germany',
    multiplier: 0.38,
    population_m: 84,
    gdp_per_capita_usd: 54000,
    healthcare_spend_pct: 12.8,
    notes: 'Largest EU pharma market. AMNOG pricing framework applies from month 13. Early access at launch price.',
  },
  {
    territory: 'France',
    code: 'France',
    multiplier: 0.28,
    population_m: 68,
    gdp_per_capita_usd: 44000,
    healthcare_spend_pct: 12.0,
    notes: 'ATU early access program. HAS assessment + CEPS negotiation. Price often 15-25% below Germany.',
  },
  {
    territory: 'Italy',
    code: 'Italy',
    multiplier: 0.22,
    population_m: 60,
    gdp_per_capita_usd: 36000,
    healthcare_spend_pct: 9.5,
    notes: 'AIFA negotiation; regional reimbursement disparities. Managed entry agreements common.',
  },
  {
    territory: 'Spain',
    code: 'Spain',
    multiplier: 0.18,
    population_m: 47,
    gdp_per_capita_usd: 32000,
    healthcare_spend_pct: 9.2,
    notes: 'National + regional (CCAA) level access. Pricing reference country for many markets.',
  },
  {
    territory: 'United Kingdom',
    code: 'UK',
    multiplier: 0.32,
    population_m: 68,
    gdp_per_capita_usd: 47000,
    healthcare_spend_pct: 11.3,
    notes: 'MHRA (post-Brexit). NICE HTA with QALY threshold £20K-£30K/QALY. Innovative Medicines Fund for oncology.',
  },
  {
    territory: 'Japan',
    code: 'Japan',
    multiplier: 0.55,
    population_m: 124,
    gdp_per_capita_usd: 34000,
    healthcare_spend_pct: 11.0,
    notes: 'PMDA regulated. Biennial drug price revisions (downward). Sakigake designation for breakthrough. 2-year lag typical post-US approval.',
  },
  {
    territory: 'China',
    code: 'China',
    multiplier: 1.20,
    population_m: 1410,
    gdp_per_capita_usd: 13700,
    healthcare_spend_pct: 5.7,
    notes: 'NMPA regulated. National Reimbursement Drug List (NRDL) negotiations apply steep discounts (30-80%). Massive patient numbers offset lower pricing.',
  },
  {
    territory: 'Rest of World',
    code: 'RoW',
    multiplier: 0.60,
    population_m: 6000,
    gdp_per_capita_usd: 12000,
    healthcare_spend_pct: 5.0,
    notes: 'Highly variable. Includes Australia, Canada, Brazil, South Korea, Taiwan, Middle East. Blended estimate.',
  },
  {
    territory: 'Canada',
    code: 'Canada',
    multiplier: 0.12,
    population_m: 40,
    gdp_per_capita_usd: 53000,
    healthcare_spend_pct: 12.2,
    notes: 'CADTH HTA. PMPRB pricing controls. Generally 25-40% below US pricing.',
  },
  {
    territory: 'Australia',
    code: 'Australia',
    multiplier: 0.08,
    population_m: 27,
    gdp_per_capita_usd: 66000,
    healthcare_spend_pct: 10.7,
    notes: 'TGA regulated. PBS listing required for broad access. PBAC assessment. Strict cost-effectiveness threshold.',
  },
];
